Pharmacokinetics and biliary concentrations of fleroxacin in cholecystectomized patients
- 1 December 1990
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 34 (12) , 2375-2380
- https://doi.org/10.1128/aac.34.12.2375
Abstract
Patients with biliary tract infections received 800 mg of fleroxacin orally once daily on five consecutive days; cholecystectomy was on day 3. Starting on the day when dose 5 was administered, serial blood and T-drain bile samples were taken for 72 h and urine was collected for 96 h. The mean (+/- the standard deviation) peak concentration in plasma was 8.2 +/- 4.0 mg/liter at 8.3 h. The harmonic mean elimination half-life was 10.5 h, which is comparable to that reported for healthy volunteers. This increase resulted from reduced renal clearance (mean [+/- standard deviation], 38 +/- 22 ml/min), as the volume of distribution in the patients (1.4 +/- 0.7 liter/kg) did not differ from that reported for healthy subjects. Maximum concentrations in T-drain bile were high (median, 22.1 mg/liter) and exceeded those measured in plasma by a factor of 2 to 3; the individual ratios of the area under the curve for bile divided by that for plasma ranged from 1.3 to 9.9. As observed in healthy volunteers, the major pathway for elimination of fleroxacin was via the kidneys. The fraction of dose 5 eliminated in the 0- to 24-h urine was reduced, however, and the fraction of the dose in the urine as the N-demethyl and N-oxide metabolites was elevated. At the dose regimen used in this study, the MICs for most pathogens that cause biliary tract infections were surpassed in plasma and bile for more than 24 h.This publication has 18 references indexed in Scilit:
- Disposition of Fleroxacin, a New Trifluoroquinolone, and Its MetabolitesClinical Pharmacokinetics, 1990
- Pharmacokinetics and tissue penetration of fleroxacin after single and multiple 400- and 800-mg-dosage regimensAntimicrobial Agents and Chemotherapy, 1988
- Comparative oral pharmacokinetics of fleroxacin and pefloxacinJournal of Antimicrobial Chemotherapy, 1988
- Clinical Pharmacokinetics of the Newer Antibacterial 4-QuinolonesClinical Pharmacokinetics, 1988
- Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humansAntimicrobial Agents and Chemotherapy, 1987
- Biliary Tract Excretion of Ofloxacin in ManDrugs, 1987
- In vitro activity of Ro 23-6240, a new difluoroquinolone derivative, compared with that of other antimicrobial agentsAntimicrobial Agents and Chemotherapy, 1986
- In vitro activity of Ro 23-6240, a new fluorinated 4-quinoloneAntimicrobial Agents and Chemotherapy, 1986
- Comparison of high-pressure liquid chromatography and microbiological assay for the determination of biliary elimination of ciprofloxacin in humansAntimicrobial Agents and Chemotherapy, 1985
- Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humansAntimicrobial Agents and Chemotherapy, 1984